Doxepin
(Redirected from Sinequan)
Tricyclic antidepressant (TCA), Antidepressant, Sleep aid (Silenor low-dose), Antihistamine (potent H1)
Doxepin (hydrochloride)
Sinequan (oral antidepressant, US brand discontinued), Silenor (low-dose for insomnia), Prudoxin / Zonalon (topical cream)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Common uses
Major depressive disorder (FDA, oral antidepressant dose)0, Anxiety disorders (FDA)0, Insomnia, sleep maintenance type (Silenor 3-6 mg, FDA)0, Chronic urticaria and pruritus (off-label, leveraging H1 antihistamine activity)0, Topical treatment of localized pruritus (Prudoxin 5% cream, FDA)0
Pharmacy
Starting dose
Depression: 25-75 mg/day to start, titrate to 75-150 mg/day at bedtime. Insomnia (Silenor): 3 mg PO 30 minutes before bedtime, max 6 mg. Topical (Prudoxin): apply to affected area every 3-4 hours
Preparations
Capsules 10, 25, 50, 75, 100, 150 mg; oral concentrate 10 mg/mL; Silenor tablets 3, 6 mg; topical cream 5% (Prudoxin, Zonalon)
US FDA Max
300 mg/day (depression, hospitalized); 150 mg/day outpatient; 6 mg/day for insomnia
Pharmacology
Routes
Oral, topical
Onset
Sleep effect from first dose; antidepressant effect over 1-4 weeks
Duration
24 hours (HS dosing)
Half-life
~15 hours (parent); nordoxepin active metabolite ~30 hours[2]
Bioavailability
~30% (oral)[2]
Pregnancy
TCA class signal; limited human data specific to doxepin.[citation needed]
Legal status
Purported mechanism
Tricyclic antidepressant with the strongest H1 antihistamine activity of any TCA, actually the most potent H1 antihistamine in clinical use, exceeding diphenhydramine on a molar basis. This is why low-dose doxepin (Silenor 3-6 mg) is uniquely sedating without anticholinergic burden at low doses: the H1 effect saturates at very low concentrations, while the muscarinic and α-adrenergic effects do not contribute meaningfully until higher antidepressant doses (75-300 mg).0 At antidepressant doses, the standard TCA mechanisms apply: serotonin and norepinephrine reuptake inhibition, anticholinergic, antihistaminergic, and α1-adrenergic antagonism. CYP2D6 and CYP2C19 substrate; CPIC TCA dosing guidance applies[1].
References
- ↑ CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants, 2016. https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/
- ↑ 2.0 2.1 2.2 FDA Prescribing Information, Silenor (doxepin tablets), Pernix/Currax, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022036lbl.pdf